Small-Cap Catalysts to Watch: May 5 - May 9

We’ve reviewed recent filings and press releases to highlight this week’s key catalysts and upcoming conferences. Stay informed and ahead of the curve!

Companies presenting at the Citizens Life Sciences Conference 2025 (May 7–8, New York, NY):

PRQR CHRS MGNX STRO GNLX NUVB SVRA SCPH RZLT PRLD GANX CLSD SNTI SLDB BCAB AVTX ACET ANTX RVPH RLYB ENGN SKYE ESPR PYPD IMMP CNTX VRCA IRWD

Companies presenting at Digestive Disease Week® (DDW) 2025 May 3–6, 2025 | San Diego, CA:

IMUX: Two abstracts discussing Immunic's phase 1/1b clinical trial of IMU-856, an orally available and systemically acting small molecule modulator that targets SIRT6 (Sirtuin 6), in patients with celiac disease, have been accepted for poster presentations on 5/6.

RDHL: Announced its support of an independent medical education grant that includes a new two-part H. Pylori CME program, developed by Medscape. The first part, "Let's Get Social About H. pylori Management," will be livestreamed on May 6 during a major gastroenterology meeting. RedHill will also be attending DDW and will be available at booth 5312.

THAR: Announced abstracts featuring clinical data on its lead drug candidate, TH104, have been accepted for presentation on 5/5.

PHAT: Will present real-world data for its first-in-class treatment VOQUEZNA®. Two Phathom-sponsored posters will be presented on May 5, 2025, at 12:30 p.m. PT in the Poster Hall at the San Diego Convention Center.

EVOK: A new abstract comparing the incidence of tardive dyskinesia (TD) in patients receiving continuous versus intermittent oral metoclopramide (OMCP) treatment has been accepted for presentation on 5/5.

ARDX: Will present data supporting the company's first-in-class retainagogue, IBSRELA® (tenapanor), as well as results from the IBS in America 2024 supplemental survey on 5/5.

PALI: Has been selected to present data from its lead program PALI-2108 for the treatment of ulcerative colitis on 5/5.

Companies participating at The Virtual Conference on Critical Minerals Presented by Maxim Group LLC | May 6th, 2025:

NB LITM UAMY

Companies exhibiting at SOF Week 2025 May 5-8, 2025 | Tampa, Florida:

KOPN: Kopin will showcase advanced displays, optics, and head-mounted systems for Augmented Reality and Virtual Reality, designed to enhance situational awareness and decision-making in both combat and training environments. Live demos of DayVAS™ and DarkWAVE™ augmented HUD modules, VR head-mounted displays, and high-contrast MicroLED displays will be featured.

AMPX: Amprius will be exhibiting at Booth 3807.

Companies participating at the Bloom Burton & Co. Healthcare Investor Conference May 5–6, 2025:

ABCL EDSA ENGN

Companies presenting at EASL 2025, the Annual Congress of the European Association for the Study of the Liver May 7–10, 2025 | Amsterdam, the Netherlands:

GALT: Will deliver a late-breaking oral presentation on May 10 featuring data from the NAVIGATE study, evaluating belapectin, a galectin-3 inhibitor, in patients with MASH cirrhosis and portal hypertension.

ABUS: Has five abstracts accepted for presentation, including one late-breaker, scheduled across May 7–8.

AVIR: Will present full Phase 2 results of its bemnifosbuvir and ruzasvir regimen for hepatitis C virus (HCV) on May 7.

SGMT: Will present three posters with additional analyses from the Phase 2b FASCINATE-2 study of denifanstat in MASH on May 7 and May 10.

MTVA: Will present a late-breaking poster highlighting Phase 2a trial data of DA-1241, a GPR119 agonist, in presumed MASH patients between May 7–10.

CMMB: Will present new clinical data on nebokitug (CM-101) for primary sclerosing cholangitis (PSC) on May 8 and 9, including proteomic analyses highlighting broad anti-fibro-inflammatory potential.

THAR: Abstracts featuring clinical data on its lead drug candidate, TH104, have been accepted for presentation on May 7.

Companies presenting at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting May 4–8, 2025 | Salt Lake City, Utah:

CLSD: Six abstracts related to the company’s suprachoroidal drug delivery platform will be presented on May 5, 7, and 8.

OCGN: The company will present on its innovative modifier gene therapy platform throughout the meeting. Presentations will highlight OCU400 for the treatment of retinitis pigmentosa (Phase 3 LiMeliGhT clinical trial), OCU410ST for the treatment of Stargardt disease (Phase 2/3 pivotal confirmatory clinical trial), and OCU410 for the treatment of geographic atrophy (Phase 2 ArMaDa clinical trial), scheduled across May 5–8.

UBX: Will present 36-week data from the ASPIRE Phase 2B study on May 7.

Other companies with key Catalysts this week:

OSRH > Will present data at the 14th International BMP Conference, May 2–6, 2025, at the University of Pennsylvania in Philadelphia.

CTOS > CEO Ryan McMonagle and CFO Chris Eperjesy will participate in a fireside chat and investor meetings at the virtual Oppenheimer 20th Annual Industrial Growth Conference on Tuesday, May 6, 2025.

LWLG > Board Director and acting VP of Engineering Siraj Nour El Ahmadi will give a keynote at ISLOP2025 in Amsterdam on May 6, focusing on hybrid silicon-organic solutions for high-speed, energy-efficient data interconnects.

ROLR > Ben Clemes, CEO of High Roller Technologies, and Seth Young, SVP of Corporate Strategy & Investor Relations, will attend the NEXT Summit: Valletta 2025 in Malta on May 7-8. Mr. Young will also join the panel, "Smart Money: The Power of Investment in a Changing World."

NVTS > Will exhibit GaN and SiC breakthroughs in AI data centers, EVs, motor drives, and industrial applications at PCIM 2025 (May 6–8, 2025).

NVNI > The Company will host an Investor Webinar on Friday, May 9th at 11:00 a.m. ET, where Nuvini CEO Pierre Shurmann will discuss financial results, strategic updates, and the FY25 outlook. A Q&A session will follow.

PHIO > Phio Pharmaceuticals CEO Robert Bitterman will present an update on INTASYL siRNA technology and the PH-762 clinical trial for skin cancers on May 7, 2025, at 2:00 p.m. EST during the Virtual Non-Deal Roadshow Series hosted by Renmark Financial Communications Inc.

SCNI > The Company will host a webinar on Wednesday, May 7th, at 11:30 AM EST / 18:30 Israel time, discussing the unmet needs in treating Pemphigus Vulgaris and SJS/TEN, and exploring Pincell's PC111, a novel monoclonal antibody targeting soluble Fas ligand (sFasL).

INO > Will present long-term data on INO-3107 at several upcoming events: at the ABEA program during COSM on May 9, showing a 81% surgery reduction in adults with recurrent respiratory papillomatosis; at the European Laryngological Society Annual Congress in Warsaw on May 9; and at the American Society of Gene and Cell Therapy poster session on May 13, discussing the treatment's success regardless of papilloma microenvironment or molecular subtype.

GANX > The Company will deliver an oral poster presentation at the IAPRD 30th World Congress on Parkinson's Disease and Related Disorders in New York City, NY, on May 10.

NBTX > Dr. Eugene Koay will present full results from the Phase 1 study evaluating JNJ-1900 (NBTXR3) after induction chemotherapy for locally advanced or borderline resectable pancreatic cancer at ESTRO 2025 on Sunday, May 4th at 11:00 AM EDT / 5:00 PM CEST. Nanobiotix will host an event on Monday, May 5th at 8:00 AM EDT / 2:00 PM CEST to review the results.

CTKB > The Company is showcasing its patented Full Spectrum Profiling™ (FSP®) technology at CYTO 2025 and AAI’s IMMUNOLOGY2025, running from May 3–7, 2025. FSP technology, designed to streamline workflows and accelerate discoveries, will be featured in demonstrations, workshops, and tutorials at these key industry events.

UIS > The Company will participate in Avasant's Empowering Beyond Summit 2025, on May 5-6 in Huntington Beach, Calif. The event brings together C-level executives to explore innovative strategies for navigating future business and technology disruptions.

INAB > The Company will present new clinical and preclinical data at ISCT 2025: an oral presentation on May 9, 2025, from 3:00–4:00 PM CDT by Mariska ter Haak on manufacturing's impact on γδ T cell products, and a poster presentation on May 8, 2025, from 6:00–7:30 PM CDT by Guoling Chen on the implementation of an electronic quality management system for cellular therapies.

BCLI > New pharmacogenomic data on NurOwn® will be presented at ISCT 2025 in New Orleans, highlighting the impact of the UNC13A genotype on clinical outcomes for ALS patients treated with NurOwn® (debamestrocel). The oral presentation will take place on May 8, 2025.

MTEK > The Company will participate in DEFEA 2025, taking place May 6–8, 2025, at the Metropolitan Expo in Athens, Greece. Maris-Tech will present its latest AI-based edge computing video intelligence solutions, including live demonstrations of its new situational awareness platform, Diamond Ultra.

AGRI > The Company has completed the purchase of 500 additional S19j Pro Antminers, which will fully rack its second Ohio site and utilize all five MW of available power. Installation and full operation are estimated to be completed by May 9, 2025.

OESX > The Company will showcase its high-quality, USA-manufactured LED lighting products at LightFair 2025 in Las Vegas, May 6-8 (Booth #1811). Orion will also host an informal investor gathering on Tuesday, May 6th.

CRVS > New interim data from the Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis will be presented in an oral session and poster at the Society for Investigative Dermatology 2025 Annual Meeting in San Diego, CA, on May 8 and 10, 2025.

OGEN > Oragenics will present at the 15th Annual Traumatic Brain Injury Conference on May 5-6, 2025, in Boston, MA. Dr. W. Frank Peacock, Chief Clinical Officer, will present an update on HeadSMART II, a major biomarker discovery trial for mild traumatic brain injury (mTBI), expected to enroll over 2,000 patients.

SHLS > Will participate in the Mizuho Virtual Fireside Chat on May 8, 2025. CEO Brandon Moss will join analyst Maheep Mandloi for the discussion. Interested investors should contact their Mizuho sales representative for more details.

TYGO > The Tigo High-Performance Off-Grid Solar package will be featured at the Annual Zonna Solar Conference, taking place from May 6 to 7 in Berlin, OH.

PSTV > The company will make new data on its lead compound REYOBIQ™ (rhenium Re186 obisbemeda) available online, with an abstract for both an oral presentation and a poster at the Nuclear Medicine and Neurooncology Conference, taking place May 9-10, 2025, in Vienna, Austria.

KULR > KULR CEO and Co-Founder Michael Mo will speak at Strategy World 2025, a global conference on AI, BI innovation, and Bitcoin treasuries for corporations. KULR is a Silver sponsor of the event, hosted by Strategy (NASDAQ:MSTR), taking place from May 5-8, 2025, in Orlando, Florida.

FOXO > The Company has signed a non-binding agreement to acquire Vector Biosource Inc. for $750,000 in Series D Preferred Stock, with additional payments tied to revenue and cash milestones. The transaction is expected to close within 45 days, estimated to be May 9, 2025, pending due diligence and working capital provisions.

NITO > The Company has signed a non-binding letter of intent (LOI) with SB Impact 4 and Solterra to invest in and develop up to four additional utility-scale Battery Energy Storage System projects in Puglia, Italy, with a combined potential capacity of 380 MW. This LOI extends the existing agreement, which grants exclusivity for evaluating and potentially acquiring these projects within 60 days. The new projects are expected to be finalized within 60 days, estimated to be around May 17, 2025.

CALC > Chief Medical Officer, Dr. Sudarshan Hebbar, will present “Experiences with AKI Clinical Trial Design” during Session 5: Clinical Trials and Drug Discovery – Part 2 at the ASN 3rd Acute Kidney Injury: From Bench to Bedside Conference on Tuesday, May 6, from 8:00–10:00 a.m. ET. Dr. Hebbar will also participate in the Session 3 roundtable discussion on “Non-Academic Careers in Science” on Wednesday, May 7, from 4:00–4:30 p.m. ET.

OCGN > Will present its gene therapy pipeline and join a panel on inherited retinal diseases at Retina World Congress on May 8, 2025, from 10:35–11:12 a.m. EDT.

--

Disclaimer: All content provided by BigTimePennys Report is for informational purposes only. The information provided should not be considered as a substitute for professional advice, analysis, or guidance. Any investment decisions made based on the information provided are solely at the user's own risk. BigTimePennys Report are not liable for any losses or damages incurred as a result of using this information. BigTimePenny is not operated by a licensed broker, a dealer, or a registered investment adviser. The Securities Litigation Reform Act of 1995 provides safe harbor protection for forward-looking statements made by companies or individuals. It should be noted that any forward-looking statements made by BigTimePennys Report, its authors, are not guarantees of future performance or results. These statements are subject to risks, uncertainties, and assumptions that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. The content provided by BigTimePennys Report does not constitute an endorsement, recommendation, or solicitation to buy, sell, or hold any securities or investment products. BigTimePennys Report, its authors, do not endorse or recommend any specific investment strategies, securities, or companies. It is crucial to conduct thorough research and seek advice from a qualified professional before making any investment decisions. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. The user assumes full responsibility for the use of the information provided by BigTimePennys Report. BigTimePennys Report, its authors, disclaim any liability for any direct, indirect, or consequential damages arising from the use or reliance on the information provided. Users should exercise their own judgment and discretion when interpreting and utilizing the information provided. Please note that the content provided by BigTimePennys Report is based on available information and sources believed to be reliable. However, market conditions and regulations may change over time, and there may be inaccuracies or errors in the information provided. It is recommended to verify the information with current and reliable sources before making any investment decisions. Investing in micro-cap companies is highly speculative and carries an extremely high degree of risk. BigTimePenny is not a fiduciary by virtue of any person's use of or access to this content. We were NOT compensated for this article.